Last reviewed · How we verify
Microlipid
Microlipid is a Small molecule drug developed by Mayo Clinic. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Microlipid |
|---|---|
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (NA)
- Omega-3D: Omega-3 for Diet-Driven Health Disparities (PHASE2)
- Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults (NA)
- Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women (NA)
- Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA) (NA)
- Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health (NA)
- Triheptanoin in Mc Ardle (PHASE2)
- The Healthy Cookie Study: Understanding How Healthy Cookies Affect Fat in the Blood, (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microlipid CI brief — competitive landscape report
- Microlipid updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about Microlipid
What is Microlipid?
Who makes Microlipid?
What development phase is Microlipid in?
Related
- Manufacturer: Mayo Clinic — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing